The roots of the Uteron Pharma’s products go back to 2002 when Belgium based Mithra Pharmaceuticals and the University of Liège decided to create a partnership to develop a hormonal intra-uterine device (IUD).
The founders of Uteron Pharma had the ambition to create an industry leader entirely dedicated to the development of women’s health products. Several new development programs were initiated with external R&D oriented organizations such as Pantarhei Bioscience, Medicines360® and EMBIC European consortium.
Initially the different product developments were structured and controlled through separate and independent legal entities. In 2010, all companies were structured and regrouped under Uteron Pharma SA. The latter was acquired by Watson Pharmaceuticals, Inc. (now Actavis plc) in January 2013.
As one of Actavis’ Centre of Excellence for women’s health products, Uteron Pharma is now focused primarily on the development of a growing portfolio of products for Actavis plc and its partners.